Literature DB >> 11754328

Detection of malignant primary hepatic neoplasms with gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted hepatocyte phase MR imaging: results of off-site blinded review in a phase-II multicenter trial.

C S Peña1, S Saini, R L Baron, B A Hamm, G Morana, R Caudana, A Giovagnoni, A Villa, A Carriero, D Mathieu, M W Bourne, M A Kirchin, G Pirovano, A Spinazzi.   

Abstract

OBJECTIVE: To investigate the efficacy of gadobenate dimeglumine (Gd-BOPTA) enhanced MR imaging for the detection of liver lesions in patients with primary malignant hepatic neoplasms.
MATERIALS AND METHODS: Thirty-one patients with histologically proven primary malignancy of the liver were evaluated before and after administration of Gd-BOPTA at dose 0.05 or 0.10 mmol/kg. T1-weighted spin echo (T1W-SE) and gradient echo (T1W-GRE) images were evaluated for lesion number, location, size and confidence by three off-site independent reviewers and the findings were compared to reference standard imaging (intraoperative ultrasound, computed tomography during arterial portography or lipiodol computed tomography). Results were analyzed for significance using a two-sided McNemar's test.
RESULTS: More lesions were identified on Gd-BOPTA enhanced images than on unenhanced images and there was no significant difference in lesion detection between either concentration. The largest benefit was in detection of lesions under 1 cm in size (7 to 21, 9 to 15, 16 to 18 for reviewers A, B, C respectively). In 68% of the patients with more than one lesion, Gd-BOPTA increased the number of lesions detected.
CONCLUSION: Liver MR imaging after Gd-BOPTA increases the detection of liver lesions in patients with primary malignant hepatic neoplasm.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11754328      PMCID: PMC2718123          DOI: 10.3348/kjr.2001.2.4.210

Source DB:  PubMed          Journal:  Korean J Radiol        ISSN: 1229-6929            Impact factor:   3.500


  20 in total

1.  Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study.

Authors:  J Petersein; A Spinazzi; A Giovagnoni; P Soyer; F Terrier; R Lencioni; C Bartolozzi; L Grazioli; A Chiesa; R Manfredi; P Marano; E L Van Persijn Van Meerten; J L Bloem; C Petre; G Marchal; A Greco; M T McNamara; A Heuck; M Reiser; M Laniado; C Claussen; H E Daldrup; E Rummeny; M A Kirchin; G Pirovano; B Hamm
Journal:  Radiology       Date:  2000-06       Impact factor: 11.105

2.  Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers.

Authors:  A Spinazzi; V Lorusso; G Pirovano; M Kirchin
Journal:  Acad Radiol       Date:  1999-05       Impact factor: 3.173

3.  Detection of malignant tumors in end-stage cirrhotic livers: efficacy of sonography as a screening technique.

Authors:  G D Dodd; W J Miller; R L Baron; M L Skolnick; W L Campbell
Journal:  AJR Am J Roentgenol       Date:  1992-10       Impact factor: 3.959

4.  Preclinical profile of Gd-BOPTA. A liver-specific MRI contrast agent.

Authors:  G Vittadini; E Felder; C Musu; P Tirone
Journal:  Invest Radiol       Date:  1990-09       Impact factor: 6.016

Review 5.  Soluble-type hepatobiliary contrast agents for MR imaging.

Authors:  C de Haën; L Gozzini
Journal:  J Magn Reson Imaging       Date:  1993 Jan-Feb       Impact factor: 4.813

6.  Interim results of phase II clinical testing of gadobenate dimeglumine.

Authors:  G Rosati; G Pirovano; A Spinazzi
Journal:  Invest Radiol       Date:  1994-06       Impact factor: 6.016

Review 7.  Understanding and optimizing use of contrast material for CT of the liver.

Authors:  R L Baron
Journal:  AJR Am J Roentgenol       Date:  1994-08       Impact factor: 3.959

8.  Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers.

Authors:  T J Vogl; W Pegios; C McMahon; J Balzer; J Waitzinger; G Pirovano; J Lissner
Journal:  AJR Am J Roentgenol       Date:  1992-04       Impact factor: 3.959

9.  Hepatic tumors: comparison of CT during arterial portography, delayed CT, and MR imaging for preoperative evaluation.

Authors:  R C Nelson; J L Chezmar; P H Sugarbaker; M E Bernardino
Journal:  Radiology       Date:  1989-07       Impact factor: 11.105

Review 10.  Gadobenate dimeglumine (Gd-BOPTA). An overview.

Authors:  M A Kirchin; G P Pirovano; A Spinazzi
Journal:  Invest Radiol       Date:  1998-11       Impact factor: 6.016

View more
  5 in total

1.  Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging.

Authors:  Jeong Min Lee; Chong Soo Kim; Ji Hyun Youk; Mi Suk Lee
Journal:  Korean J Radiol       Date:  2003 Jan-Mar       Impact factor: 3.500

2.  Follow-up result afters negative findings on unenhanced hepatic MR imaging for hepatic metastasis from rectal cancer.

Authors:  Joon Seok Lim; Myeong-Jin Kim; Kang Young Lee; Nam Kyu Kim; Jin-Sub Choi; Joo Hee Kim; Young Taik Oh; Won Ho Kim; Ki Whang Kim
Journal:  Korean J Radiol       Date:  2004 Oct-Dec       Impact factor: 3.500

Review 3.  Pediatric liver tumors--a pictorial review.

Authors:  Priyanka Jha; Soni C Chawla; Sidhartha Tavri; Chirag Patel; Charles Gooding; Heike Daldrup-Link
Journal:  Eur Radiol       Date:  2008-08-06       Impact factor: 5.315

4.  Gadobenate dimeglumine-enhanced liver MR imaging: value of dynamic and delayed imaging for the characterization and detection of focal liver lesions.

Authors:  Young Kon Kim; Jeong Min Lee; Chong Soo Kim
Journal:  Eur Radiol       Date:  2003-11-05       Impact factor: 5.315

5.  A Glimpse on Trends and Characteristics of Recent Articles Published in the Korean Journal of Radiology.

Authors:  Yeon Hyeon Choe
Journal:  Korean J Radiol       Date:  2019-12       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.